



Research ... For the Future

Len Lichtenfeld, MD, MACP
Interim Chief Medical and Scientific Officer

OUR MISSION IS TO

SAVE LIVES,

**CELEBRATE
LIVES,**

&

LEAD THE FIGHT

FOR A WORLD WITHOUT CANCER.

ATTACKING CANCER FROM EVERY ANGLE

We are **Activists**

Convening relentless partners
for awareness and impact

ACS CAN
Cancer Control Roundtables
Coaches vs. Cancer
CEOs Against Cancer
Corporate partnerships
Health Systems partnerships

We build **Communities**

United to fight cancer with
access to treatment and compassion

Hope Lodge
Road To Recovery
CHANGE Grants
Relay For Life and Making Strides
Galas and golf events

We deliver **Breakthroughs**


Investing in innovative research to
develop game-changing approaches

Extramural research grants
Cancer Prevention Studies
ACS journals and publications
Behavioral Research Center
ACS BrightEdge Ventures

We provide **Direction**

A passionate ally, empowering people
with information & answers

NCIC
Patient Navigation Program
cancer.org
Cancer screening guidelines
Health professional and patient education



CANCER PREVENTION STUDIES (CPS)

Intramural Research



Smoking

Our early studies linking smoking with lung cancer and higher overall death rates played an important role in The Surgeon General's landmark 1964 report showing that smoking causes lung cancer.



Obesity

CPS-I revealed the first epidemiologic evidence that obesity increases risk of premature death, and CPS-II established the link between obesity and death from breast, colorectal, and other cancers.



Aspirin

CPS-II was the first prospective study to find a link between regular aspirin use and lower risk of colorectal cancer, opening the door to more research on aspirin and risk of other cancers.



Diet & Exercise

Our studies revealed that high intake of red and processed meats and alcohol, low physical activity, and longer sitting time increase risk of cancer or mortality.




Genetics

CPS-II data and biospecimens have been included in the identification or validation of nearly every confirmed breast, prostate, and pancreatic cancer genetic susceptibility variant known to date.

CANCER FACTS & FIGURES

Intramural Research



CANCER FACTS & FIGURES



CANCER FACTS & FIGURES FOR AFRICAN AMERICANS



CANCER PREVENTION & EARLY DETECTION FACTS & FIGURES



CANCER FACTS & FIGURES FOR HISPANICS/LATINOS



BREAST CANCER FACTS & FIGURES



CANCER TREATMENT & SURVIVORSHIP FACTS & FIGURES



COLORECTAL CANCER FACTS & FIGURES



GLOBAL CANCER FACTS & FIGURES



ACS AND EXTRAMURAL RESEARCH

Long-term commitment, strategic investments, successful outcomes

ACS IS THE LARGEST NON-GOVERNMENTAL FUNDER OF CANCER RESEARCH IN THE U.S.

- Over \$4.8B in research funded since 1946
- Very often first major grant for young researchers
- 70% of grant recipients will obtain NIH funding
- 47 Nobel Laureates funded prior to their award
- 70% of NCI Cancer Center Directors

>33,00 GRANTS


>24,000 INVESTIGATORS

>1,100 INSTITUTIONS

2017 FUNDING BY SELECTED CANCER TYPES

Total Awarded: \$98.4 million

BREAST CANCER	\$12.4 million
COLON AND RECTAL CANCER	\$9.2 million
LUNG CANCER	\$8.1 million
LEUKEMIA	\$6.2 million
PROSTATE CANCER	\$6 million
PANCREATIC CANCER	\$4.9 million
SKIN CANCER	\$4.1 million
OVARIAN CANCER	\$2.4 million
BLOOD CANCER	\$2 million
BRAIN TUMOR	\$1.9 million
LIVER CANCER	\$1.9 million
HEAD AND NECK CANCER	\$1.1 million
BLADDER CANCER	\$1 million
MYELOMA	\$0.43 million
OTHER CANCER TYPES*	\$8 million



CANCER RESEARCH INVESTMENT PLATFORM

New Framework



Launch

Launch careers of most innovative young cancer scientists in the U.S.

- Top 10-15% of scientists selected by rigorous, competitive, and independent peer review
- Breakthroughs in foundational cancer research on cause, prevention, detection, treatment and survivorship
- Investment to change the future of cancer



Boost

More focused approach on providing support for projects to catapult the foundational research to the next level

- Any aspect of bench to bedside to community research continuum
- Mission Boost – patient/population focused work
- Discovery Boost – all other cancer research
- Can be individual awards or teams assembled around ACS Professors



Accelerate

Fund companies with the most promising cancer solutions: (diagnostics, therapeutics, devices, technologies & service)

- ACS BrightEdge Ventures initiative to invest for-profit companies with today's solutions
- Accelerate commercial adoption to allow for patients to receive access to novel and innovative solutions at scale
- Will underwrite for mission and returns

MISSION BOOST GRANTS

REINVEST IN ACS GRANTEES WITH ‘BOOST’ RESOURCES FOR HIGHLY INNOVATIVE PROJECTS TO ACCELERATE CLINICAL IMPACT.

- **Current or past ACS grantees propose high risk/ high reward projects in two stages:**
 1. Stage 1: Project that enables the study of a new drug, device, or procedure in patients. 24 months / \$240,000
 2. Stage 2: Second grant awarded if initial project milestones are reached. 18 months / \$360,000

THEORYLAB

- TheoryLab is an online community exclusively for current and former American Cancer Society grantees, mentors, reviewers, and stakeholders
- Two guiding principles: creativity and innovation
- Created to inspire transdisciplinary collaborations to define and investigate the most exciting cancer research opportunities

The screenshot shows the TheoryLab website interface. At the top, there is a navigation bar with the TheoryLab logo, a search bar, and a user profile for Joe Cotter. Below the navigation bar is a main header with the text "Welcome to TheoryLab" and "The American Cancer Society's Online Collaborative Innovation Community". The central banner features a network diagram with the words "INSPIRE", "SUPPORT", "COLLABORATE", "SHARE", "INNOVATE", and "BREAKTHROUGH". Below the banner, there is a "Start a Discussion" section with a form for posting, polling, or asking a question. To the right, there is a "My Groups" section listing various groups like "ACS advocacy and outreach" and "Adolescent and Young Adult Oncology". At the bottom, there is a "Featured Topics" section with three image-based cards: "HOW TO USE THEORYLAB", "METASTASIS", and "COOL IMAGES FROM THE LAB".

PARTNERSHIPS

MELANOMA RESEARCH ALLIANCE

- Adverse Events Associated with Immune Therapy
- Metastasis

GLOBAL CENTER FOR MEDICAL INNOVATION

- Mission Boost Projects – Medical Devices

ST. BALDRICK'S FOUNDATION

- Innovative Projects in the Context of Clinical Trials

**5-6 OTHERS IN
ACTIVE
CONVERSATIONS
OR NEGOTIATIONS**

CANCER RESEARCH INVESTMENT PLATFORM

Advances in Biotech are Creating New Opportunities to Fund Technology and Therapeutic Companies

AMERICAN CANCER SOCIETY RESEARCH

Investing in today's problems for tomorrow solutions

Launch

Invests in the future of cancer research

Focus:

The best and brightest in basic science



Boost

Brings innovation closer to commercialization by exploring applications

Focus:

Bringing discoveries closer to commercialization



Accelerate

Targets most promising companies in oncology

Focus:

Early- to late-stage companies

BRIGHTEDGE

Investing in today's solutions

BRIGHTEDGE VENTURES

- Charitably funded cancer-specific impact fund
- Evergreen, perpetual fund model, with all proceeds from liquidity events reinvested into the Society's life-saving work
- Impact Donors will receive institutional quality quarterly reports, visibility into our network and deal flow pipeline
- Every donated dollar attributed to individual donors for transparency, with visibility to fund performance and compounding effect generated from returns
- Professionally managed, with annual Impact Donor Conference to meet our company CEOs, hear from members of our investor and clinical advisory boards and network with other philanthropically minded donors



THANK YOU

Len Lichtenfeld, MD, MACP
Interim Chief Medical and Scientific Officer
Len.Lichtenfeld@cancer.org